Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Amberstone Biosciences Secures $12M Series A

2022-01-03
LAGUNA HILLS, CA, Amberstone Biosciences, an emerging biotherapeutics company, announced the completion of a $12M Series A financing round.
Amberstone Biosciences, an emerging biotherapeutics company, announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders.

Incorporated in 2018, Amberstone Biosciences is an emerging biotherapeutics company developing a novel class of targeted and conditionally active immunotherapeutics to treat solid tumor cancers and other diseases. Amberstone Biosciences' pipeline is driven by an innovative high-throughput single-cell functional discovery platform and strong expertise in an interdisciplinary field of biology, engineering, and therapeutic development.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors